Racura Oncology Moves Forward in Phase 1 Trial of RC220 for Lung Cancer Treatment#Australia#Sydney#EGFR-Mutant#Racura_Oncology#RC220
Racura Oncology Moves Forward in Phase 1 Trial of RC220 for Lung Cancer Treatment
Racura Oncology has received approval to escalate the dosage of its drug RC220 in the HARNESS-1 trial, aimed at treating EGFR-mutant lung cancer, marking a significant step in cancer research.
third-news.com
October 12, 2026 at 11:09 AM
Racura Oncology Moves Forward in Phase 1 Trial of RC220 for Lung Cancer Treatment#Australia#Sydney#EGFR-Mutant#Racura_Oncology#RC220
Racura Oncology Initiates Phase 1 HARNESS-1 Clinical Trial for Lung Cancer Treatment#Australia#Sydney#Osimertinib#Racura_Oncology#RC220
Racura Oncology Initiates Phase 1 HARNESS-1 Clinical Trial for Lung Cancer Treatment
Racura Oncology has begun the HARNESS-1 Phase 1 clinical trial, examining RC220 combined with osimertinib in EGFR-mutant non-small cell lung cancer.
third-news.com
June 25, 2026 at 3:09 PM
Racura Oncology Initiates Phase 1 HARNESS-1 Clinical Trial for Lung Cancer Treatment#Australia#Sydney#Osimertinib#Racura_Oncology#RC220
Racura Oncology Receives Positive SRC Recommendation for CPACS Trial Continuing with RC220#Australia#Sydney#Racura_Oncology#RC220#CPACS_Clinical_Trial
Racura Oncology Receives Positive SRC Recommendation for CPACS Trial Continuing with RC220
Racura Oncology's ongoing CPACS clinical trial for RC220 has received a positive recommendation from its Safety Review Committee, paving the way for further development.
third-news.com
May 15, 2026 at 11:08 AM
Racura Oncology Receives Positive SRC Recommendation for CPACS Trial Continuing with RC220#Australia#Sydney#Racura_Oncology#RC220#CPACS_Clinical_Trial
Racura Oncology Unveils Mechanism of (E,E)-bisantrene's Anti-Cancer Action#c-MYC#Racura_Oncology#(E#E)-bisantrene
Racura Oncology Unveils Mechanism of (E,E)-bisantrene's Anti-Cancer Action
Racura Oncology has discovered a pivotal mechanism behind (E,E)-bisantrene's anti-cancer effects, silencing the c-MYC oncogene through G4-DNA stabilization.
third-news.com
May 6, 2026 at 11:07 AM
Racura Oncology Unveils Mechanism of (E,E)-bisantrene's Anti-Cancer Action#c-MYC#Racura_Oncology#(E#E)-bisantrene